Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Aprea Therapeutics, Inc. - Common Stock (NQ:APRE)

1.090 +0.183 (+20.11%)

Streaming Delayed Price Updated: 12:27 PM EDT, Apr 17, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	648,788
Open	0.9077
Bid (Size)	1.090 (1,500)
Ask (Size)	1.100 (3,300)
Prev. Close	0.9077
Today's Range	0.9077 - 1.120
52wk Range	0.5480 - 2.220
Shares Outstanding	5,979,292
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

April 01, 2026

Funding will support ongoing development of APR-1051, including expansion into selected patient populations where WEE1 mechanism is well suited

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

March 30, 2026

From Aprea Therapeutics

Via GlobeNewswire

Performance

YTD	+27.8%	+27.8%
1 Month	+39.4%	+39.4%
3 Month	+21.9%	+21.9%
6 Month	-29.2%	-29.2%
1 Year	-29.1%	-29.1%

More News

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

March 30, 2026

From Aprea Therapeutics

Via GlobeNewswire

Gapping stocks in Monday's session ↗

March 16, 2026

Via Chartmill

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

March 16, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial ↗

February 18, 2026

Via Stocktwits

The market is filled with gapping stocks in Wednesday's session. ↗

February 18, 2026

Via Chartmill

Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 Trial

February 18, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline Growth

February 12, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

February 04, 2026

From Aprea Therapeutics

Via GlobeNewswire

Let's take a look at the stocks that are in motion in today's session. ↗

January 30, 2026

Via Chartmill

Check out the stocks that are attracting the most attention and driving market activity. ↗

January 30, 2026

Via Chartmill

In today's session, these stocks are experiencing unusual volume. ↗

January 30, 2026

Via Chartmill

Top movers analysis in the middle of the day on 2026-01-30: top gainers and losers in today's session. ↗

January 30, 2026

Via Chartmill

What's going on in today's after hours session ↗

January 29, 2026

Via Chartmill

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

January 29, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

January 29, 2026

From Aprea Therapeutics

Via GlobeNewswire

Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026

December 18, 2025

From Aprea Therapeutics

Via GlobeNewswire

Game-Changing News: BEAT, APRE, TOON, MNTS, PRSO, PNPNF, SIGL – Stocks Under $1 Look Now

December 10, 2025

Via AB Newswire

Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq Rules

December 09, 2025

From Aprea Therapeutics

Via GlobeNewswire

Datavault AI (NASDAQ: DVLT) a Promising FY26 Forward Multiple, Reports +148% Q3, Expands Tokenization Globally – More Similar Stocks Inside.

November 20, 2025

Via AB Newswire

Aprea Therapeutics (Nasdaq: APRE) Advances Cancer Pipeline as Maxim Group Sets $10 Price Target

November 18, 2025

Via AB Newswire

Signal Advance (OTC: SIGL) CEO on The Street Podcast – Unveiling Physics-Based Encryption Built for the AI and Quantum Computing Era

November 12, 2025

Via AB Newswire

Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update

November 12, 2025

From Aprea Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Aprea Therapeutics, Inc. - Common Stock publicly traded?

Yes, Aprea Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Aprea Therapeutics, Inc. - Common Stock trade on?

Aprea Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Aprea Therapeutics, Inc. - Common Stock?

The ticker symbol for Aprea Therapeutics, Inc. - Common Stock is APRE on the Nasdaq Stock Market

What is the current price of Aprea Therapeutics, Inc. - Common Stock?

The current price of Aprea Therapeutics, Inc. - Common Stock is 1.090

When was Aprea Therapeutics, Inc. - Common Stock last traded?

The last trade of Aprea Therapeutics, Inc. - Common Stock was at 04/17/26 12:27 PM ET

What is the market capitalization of Aprea Therapeutics, Inc. - Common Stock?

The market capitalization of Aprea Therapeutics, Inc. - Common Stock is 6.52M

How many shares of Aprea Therapeutics, Inc. - Common Stock are outstanding?

Aprea Therapeutics, Inc. - Common Stock has 7M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.